This is a randomized blind clinical trial for comparing oral drug (Fingolimode) with high dose interferone (S.C) in treating symptoms and reduction of relapse rates in MS patients.50 patients with inclusion criteria who were under treatment of low dose Betaferon (Cinnovex.Avonex.Actovex) and have treatment failure. (more than one relapse during one year) will categorize in two randomized selected groups .we prescribe Fingolimode in 0.5 mg daily for first group and Betaferon (high dose) (Rebif.Actorif.Recigen) in second one through S.C every three days .patients will be evaluated through months 0.3.9.12.18 (5 visits after intervention) by neurologist who will not interfer in any parts of study and will not be aware of which patients will take which treatment. patients will analysis through E.D.S.S for surveying the intensity of disease or relapses.MRI will also be take through months 0 and 18.at last data will be analysed.